Descripción de la empresa
Geron Corporation operates as a commercial-stage biopharmaceutical entity dedicated to the development of therapeutic products primarily within the oncology sector. The company functions within the broader Healthcare sector and specifically the Biotechnology industry, where its focus is on advancing treatments for conditions such as myelodysplastic syndromes using agents like RYTELO. In terms of scale, Geron holds a market capitalization of $1.11B, generated annual revenue of $183.88M over the trailing twelve months, and employs 258 individuals. These valuation and revenue figures position the company as a mid-cap entity with a specialized product pipeline rather than a diversified conglomerate, indicating a position where growth is heavily dependent on the success of specific drug approvals and clinical developments.
Salud financiera
The company reported revenue of $183.88M for the trailing twelve months, yet it recorded a net income loss of $83,500,000 and an EBITDA of $-51,079,000. The substantial gap between positive revenue and significant negative net income reveals a cost structure characterized by high operating expenses, likely driven by research and development costs typical of biotechnology firms. Free cash flow stands at $-78,356,248, which indicates that the company is currently burning cash and lacks immediate financial flexibility to fund operations without external capital or existing reserves. Despite the negative earnings, the balance sheet maintains $357.92M in cash against $121.99M in debt, suggesting a liquidity buffer, although the debt-to-equity ratio of 54.01% indicates a leveraged position relative to shareholder equity. Profitability metrics are under pressure, evidenced by a gross margin of 97.4%, an operating margin of -17.7%, and a profit margin of -45.4%. While the high gross margin suggests efficient production of therapeutics, the negative operating and profit margins confirm that overhead costs currently exceed the gross profit generated. Short-term liquidity appears robust given a current ratio of 4.66, implying the company has more than four times the current assets required to cover its current liabilities. Return on equity is recorded at -33.0% and return on assets at -5.5%, metrics that reveal management is currently unable to generate positive returns on the capital invested or the assets held.
Evaluación de valoración
Valuation multiples for Geron reflect its unprofitable status, with a trailing P/E ratio of N/A and a forward P/E of 21.75. The absence of a trailing P/E while a forward P/E exists implies that the market is pricing in anticipated future earnings that do not yet exist in the current financial statements. The price-to-book ratio stands at 4.93, indicating that the stock trades at a significant premium over its net asset value. Additionally, the price-to-sales ratio is 6.06 and the EV/EBITDA is -17.20, suggesting that investors are valuing the company based on its sales potential and asset base rather than current profitability. Price volatility over the last year is defined by a 52-week high of $2.01 and a 52-week low of $1.04. Relative to this trading range, the current market price sits below the upper bound, reflecting the speculative nature of a biotech firm with negative earnings. The stock exhibits a beta of 0.67, which means its price volatility is lower than the broader market, moving with less intensity than the general equity index.
Growth & Income
Revenue growth year-over-year is recorded at 1.0%, while earnings growth is listed as N/A due to the company's current lack of profitability. The divergence between positive revenue growth and negative earnings implies that top-line expansion is not yet translating into bottom-line gains, a common scenario in early-stage biopharmaceutical development. Geron is a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, confirming that the company does not distribute cash to shareholders. Instead, the firm retains all earnings and cash reserves to reinvest into its research pipeline and operational needs rather than paying dividends. Consequently, the overall growth and income profile is characterized by capital appreciation potential driven by clinical milestones rather than income generation or dividend yields.